After architecting Agios’ oncology exit and R&D pivot, Jackie Fouse hands keys to former Alexion exec
On Aug. 8, Agios will get a new face, as Jackie Fouse switches to board chair and former Alexion executive Brian Goff steps in to lead the C-suite of a 14-year-old biotech in the early days of its transition to a rare disease drug developer.
The early August switch-up gives Fouse, who served in the upper echelons of Celgene leading up to the massive Bristol Myers Squibb exit, the chance to focus her days on “environmentally-oriented projects” in Cape Cod and conservation areas in Massachusetts that have long sat on her wish list, she told Endpoints News ahead of the Tuesday post-closing bell disclosure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
